Drugs / Dersalazine
Dersalazine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00808977 | Dec 2008 → Jun 2010 | ulcerative colitis | Palau Pharma S.L.U. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dersalazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00808977 ↗ |
| Known as | Dersalazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106406 ↗ |
| Known as | Dersalazine sodium | “Dersalazine sodium is an inhibitor of platelet activator factor with potential efficacy in patients with ulcerative colitis through an alternative mechanism of action.” PMID 25192498 ↗ Nov 2014 |
| Known as | UR-12746 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106406 ↗ |
| Action | Inhibit | “Dersalazine sodium is an inhibitor of platelet activator factor” PMID 25192498 ↗ Nov 2014 |
| Modality | Small molecule | — CHEMBL2106406 ↗ |